Table 2.
Changes in urinary albumin-to-creatinine ratio, blood pressure (difference in change between aliskiren and control group) and discontinuations due to adverse events in randomised controlled trials.
| Trial | Baseline ACR (aliskiren group) | % change in urine ACR | Baseline sitting blood pressure (aliskiren group) | Change in blood pressure (aliskiren − control) | Discontinuations due to adverse event – aliskiren group | Discontinuations due to adverse event – control group |
|---|---|---|---|---|---|---|
| AVOID | 513 | −18% | 135/78 mmHg | −2/1 mmHg | 17 (5.6%) | 19 (6.4%) |
| ALTITUDE | 206 | −16% | 137/74 mmHg | −1.9/1 mmHg | 563 (13.2%) | 437 (10.2%) |
| ASPIRE | NR | NR | NR | NR | NR | NR |
| ASTRONAUT | NR | NR | NR | NR | NR | NR |
| AQUARIUS | NR | NR | 132/77 mmHg | −3/0.6 mmHg | NR | NR |
| ATMOSPHERE | NR | NR | 127 mmHg (SBP) | NR | NR | NR |
ALTITUDE: Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints; ATMOSPHERE: Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure; ASPIRE: Aliskiren Study in Post-MI Patients to Reduce Remodelling; ASTRONAUT: Aliskiren Trial on Acute Heart Failure Outcomes; AQUARIUS: Aliskiren Quantitative Atherosclerosis Regression Intravascular Ultrasound Study; ACR: albumin-to-creatinine ratio; NR: not reported; SBP: systolic blood pressure.